Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry. Issue 5 (8th May 2022)

• Record Type: Journal Article
• Authors: Tilch, Marie-Kristin; Visco, Carlo; Kinda, Sandra; Hermine, Olivier; Kohn, Milena; Besson, Caroline; Lamure, Sylvain; Duléry, Rémy; Ragaini, Simone; Eyre, Toby A.; Van Meerten, Tom; Ohler, Anke; Eckerle, Steffen; Dreyling, Martin; Hess, Georg; Giné, Eva; Gomes da Silva, Maria
• Is Part Of: HemaSphere. Volume 6:Issue 5(2022)
• Page Start: e0711
• Publication Date: 2022-05-08
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/HS9.0000000000000711
• Languages: English
• ISSNs: 2572-9241

Abstract

Abstract : Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL patients with COVID-19 infection were collected, aiming to identify risk factors for mortality from COVID-19. In our retrospective, multicenter, international study, we collected data from 63 MCL patients with a median age of 64 years (range, 44–84) in 9 countries with evidence of a COVID-19 infection between February 2020 and October 2021. The overall mortality rate was high (44.4%), especially in hospitalized patients (61%) and in patients with need for intensive care unit care (94%). Patients receiving rituximab had significantly poorer survival than patients not receiving rituximab ( P = 0.04). Our data highlight the importance of prevention strategies and underline the need for effective vaccination in this vulnerable cohort.